We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Collaboration to Develop NMR Hypersense Technology

By Biotechdaily staff writers
Posted on 17 Oct 2005
Oxford Instruments Molecular Biotools (OIMBL, Oxon, UK) has entered into three landmark collaborative agreements with Pfizer Global R&D (Sandwich, UK), Queen Mary and Westfield College, University of London (London, UK), and the University of Birmingham Institute for Cancer Studies (UK). More...
These agreements allow for the development of sophisticated and innovative applications in nuclear magnetic resonance (NMR) technology, utilizing the dramatic enhancement in the signal-to-noise ratio provided by HyperSense.

HyperSense is a novel in vitro dynamic nuclear polarization (DNP) polarizer capable of amplifying the baseline signal-to-noise ratio of NMR systems by a factor of up to 10,000 for 1D NMR spectral analysis. HyperSense is the first commercial product of its kind that enables scientists to attain an excellent level of information quality and richness, while opening up the field of practical NMR analysis to totally new areas of research. It is a modular instrument that will attach to any traditional NMR system, to deliver polarization-enhanced samples using a solid-state dynamic nuclear polarization (DNP) technique recently licensed from GE Healthcare (Waukesha, WI, USA).

The collaborators, representing some of the major NMR groups across academia and industry in the United Kingdom, will evaluate different aspects of the use of the enhanced levels of signal-to-noise ratio provided by HyperSense, in applications across life science research, pharmaceuticals, and chemistry.

At the biomolecular NMR spectroscopy laboratory at the University of Birmingham, Prof. Michael Overduin and Dr. Ulrich Günther of the CRC Institute for Cancer Studies (Birmingham, UK) will use HyperSense to conduct additional studies to identify biologic markers for different types of cancer and to develop new methods for determining the kinetics and dynamics of protein-ligand interactions.

The diversity of NMR research applications directly reflects the flexibility of applications for HyperSense. By providing the information richness of NMR and enhancing the signal-to-noise ratio by up to 10,000 fold, this technique avoids time-consuming and labor-intensive enrichment processes that were once a requisite.


Related Links:
Oxford Instruments Molecular Biotools

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.